Table 2.
AEs from csDMARD use
| Participants | |
|---|---|
| Rheumatologist-estimated | N = 100 |
| AE rate in patients using various csDMARDs (%), median (IQR) | |
| MTX | 15.0 (20.0) |
| LEF | 15.0 (10.0) |
| SASP | 10.0 (10.0) |
| HCQ | 10.0 (5.0) |
| Patient-reported | N = 400 |
| Experienced AEs after taking prescribed csDMARD, n (%) | |
| MTX (n = 202) | 80 (39.6) |
| LEF (n = 172) | 58 (33.7) |
| SASP (n = 35) | 17 (48.6) |
| HCQ (n = 55) | 8 (14.6) |
| Changed csDMARD, n (%) | 113 (28.3) |
| Notified rheumatologist about AEs, n (%)a | 116 (85.9) |
AE adverse event, csDMARD conventional synthetic disease-modifying antirheumatic drug, HCQ hydroxychloroquine, IQR interquartile range, LEF leflunomide, MTX methotrexate, SASP salazosulfapyridine
an = 135